S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AxoGen, Inc. stock logo
AXGN
AxoGen
$6.55
-5.6%
$8.68
$3.45
$10.83
$286.17M1.03418,059 shs237,595 shs
ViewRay, Inc. stock logo
VRAY
ViewRay
$0.34
$0.02
$4.96
$4.59M0.817.51 million shs108.50 million shs
Zynex, Inc. stock logo
ZYXI
Zynex
$11.45
-5.1%
$12.57
$6.88
$14.75
$368.35M0.48242,258 shs177,419 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AxoGen, Inc. stock logo
AXGN
AxoGen
-0.86%-7.47%-9.99%-14.74%-29.54%
ViewRay, Inc. stock logo
VRAY
ViewRay
0.00%0.00%0.00%0.00%-97.95%
Zynex, Inc. stock logo
ZYXI
Zynex
-0.66%-1.87%-4.58%+16.73%+3.96%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AxoGen, Inc. stock logo
AXGN
AxoGen
1.6792 of 5 stars
3.53.00.00.00.02.50.6
ViewRay, Inc. stock logo
VRAY
ViewRay
1.5098 of 5 stars
3.00.00.04.40.01.70.0
Zynex, Inc. stock logo
ZYXI
Zynex
2.4668 of 5 stars
3.51.00.00.00.01.73.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AxoGen, Inc. stock logo
AXGN
AxoGen
3.00
Buy$10.6762.85% Upside
ViewRay, Inc. stock logo
VRAY
ViewRay
2.00
Hold$1.33∞ Upside
Zynex, Inc. stock logo
ZYXI
Zynex
3.00
Buy$18.0057.21% Upside

Current Analyst Ratings

Latest VRAY, AXGN, and ZYXI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/1/2024
Zynex, Inc. stock logo
ZYXI
Zynex
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$13.00 ➝ $15.00
3/1/2024
Zynex, Inc. stock logo
ZYXI
Zynex
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$20.00 ➝ $21.00
1/19/2024
AxoGen, Inc. stock logo
AXGN
AxoGen
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$12.00
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AxoGen, Inc. stock logo
AXGN
AxoGen
$159.01M1.80N/AN/A$2.22 per share2.95
ViewRay, Inc. stock logo
VRAY
ViewRay
$105.86M0.00N/AN/A$0.45 per share0.00
Zynex, Inc. stock logo
ZYXI
Zynex
$184.32M2.00$0.39 per share29.52$1.36 per share8.42

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AxoGen, Inc. stock logo
AXGN
AxoGen
-$21.72M-$0.52N/AN/AN/A-13.66%-22.38%-11.24%5/2/2024 (Confirmed)
ViewRay, Inc. stock logo
VRAY
ViewRay
-$107.33M-$0.60N/AN/AN/A-104.30%-120.48%-42.39%N/A
Zynex, Inc. stock logo
ZYXI
Zynex
$9.73M$0.2742.4112.18N/A5.28%16.82%7.05%4/25/2024 (Estimated)

Latest VRAY, AXGN, and ZYXI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
AxoGen, Inc. stock logo
AXGN
AxoGen
-$0.10N/A+$0.10N/AN/AN/A  
3/5/2024Q4 2023
AxoGen, Inc. stock logo
AXGN
AxoGen
-$0.20-$0.09+$0.11-$0.09$42.70 million$42.92 million
2/29/2024Q4 2023
Zynex, Inc. stock logo
ZYXI
Zynex
$0.17$0.04-$0.13$0.04$54.53 million$47.28 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AxoGen, Inc. stock logo
AXGN
AxoGen
N/AN/AN/AN/AN/A
ViewRay, Inc. stock logo
VRAY
ViewRay
N/AN/AN/AN/AN/A
Zynex, Inc. stock logo
ZYXI
Zynex
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AxoGen, Inc. stock logo
AXGN
AxoGen
0.71
2.89
2.14
ViewRay, Inc. stock logo
VRAY
ViewRay
N/A
1.16
0.91
Zynex, Inc. stock logo
ZYXI
Zynex
1.26
4.74
4.03

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AxoGen, Inc. stock logo
AXGN
AxoGen
80.29%
ViewRay, Inc. stock logo
VRAY
ViewRay
92.97%
Zynex, Inc. stock logo
ZYXI
Zynex
29.68%

Insider Ownership

CompanyInsider Ownership
AxoGen, Inc. stock logo
AXGN
AxoGen
7.21%
ViewRay, Inc. stock logo
VRAY
ViewRay
2.50%
Zynex, Inc. stock logo
ZYXI
Zynex
52.13%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AxoGen, Inc. stock logo
AXGN
AxoGen
42643.69 million40.54 millionOptionable
ViewRay, Inc. stock logo
VRAY
ViewRay
295183.40 million178.82 millionOptionable
Zynex, Inc. stock logo
ZYXI
Zynex
1,10032.17 million15.40 millionOptionable

VRAY, AXGN, and ZYXI Headlines

SourceHeadline
Zynex Sets First Quarter 2024 Earnings CallZynex Sets First Quarter 2024 Earnings Call
prnewswire.com - April 18 at 9:15 AM
3 Industrial Stocks Short Sellers Are Hammering: Cracks in the Foundation?3 Industrial Stocks Short Sellers Are Hammering: Cracks in the Foundation?
investorplace.com - April 2 at 2:58 PM
Zynex Earns Prestigious 2024 Top Workplaces USA Employer Recognition AwardZynex Earns Prestigious 2024 Top Workplaces USA Employer Recognition Award
prnewswire.com - April 2 at 9:15 AM
With 51% ownership, Zynex, Inc. (NASDAQ:ZYXI) insiders have a lot riding on the companys futureWith 51% ownership, Zynex, Inc. (NASDAQ:ZYXI) insiders have a lot riding on the company's future
finance.yahoo.com - March 30 at 11:16 AM
ZYXI Aug 2024 20.000 callZYXI Aug 2024 20.000 call
finance.yahoo.com - March 16 at 6:46 AM
Zynex Inc.Zynex Inc.
wsj.com - March 15 at 6:06 PM
Zynex Full Year 2023 Earnings: Misses ExpectationsZynex Full Year 2023 Earnings: Misses Expectations
finance.yahoo.com - March 3 at 9:09 AM
Zynex, Inc. (ZYXI) Q4 2023 Earnings Call TranscriptZynex, Inc. (ZYXI) Q4 2023 Earnings Call Transcript
seekingalpha.com - March 2 at 7:09 PM
Zynex, Inc. (NASDAQ:ZYXI) Q4 2023 Earnings Call TranscriptZynex, Inc. (NASDAQ:ZYXI) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 2 at 9:07 AM
Heres what to expect from Zynexs earningsHere's what to expect from Zynex's earnings
markets.businessinsider.com - March 1 at 5:41 PM
Zynex Price Target Raised by RBC Capital, HC Wainwright AnalystsZynex Price Target Raised by RBC Capital, HC Wainwright Analysts
finance.yahoo.com - March 1 at 12:40 PM
Zynex Inc. (ZYXI) Q4 Earnings and Revenues Miss EstimatesZynex Inc. (ZYXI) Q4 Earnings and Revenues Miss Estimates
zacks.com - February 29 at 6:21 PM
Zynex: Q4 Earnings InsightsZynex: Q4 Earnings Insights
benzinga.com - February 29 at 5:39 PM
Zynex GAAP EPS of $0.04 misses by $0.13, revenue of $47.28M misses by $8.34MZynex GAAP EPS of $0.04 misses by $0.13, revenue of $47.28M misses by $8.34M
msn.com - February 29 at 5:39 PM
Zynex Inc (ZYXI) Reports 17% Revenue Growth in FY 2023, Announces New $20 Million Stock ...Zynex Inc (ZYXI) Reports 17% Revenue Growth in FY 2023, Announces New $20 Million Stock ...
finance.yahoo.com - February 29 at 5:39 PM
Zynex Reports Fourth Quarter and Full Year 2023 Financial ResultsZynex Reports Fourth Quarter and Full Year 2023 Financial Results
finance.yahoo.com - February 29 at 4:23 PM
Zynex Reports Fourth Quarter and Full Year 2023 Financial ResultsZynex Reports Fourth Quarter and Full Year 2023 Financial Results
prnewswire.com - February 29 at 4:01 PM
Earnings Preview: ZynexEarnings Preview: Zynex
benzinga.com - February 28 at 2:18 PM
Zynex Sets Fourth Quarter and Full Year 2023 Earnings CallZynex Sets Fourth Quarter and Full Year 2023 Earnings Call
finance.yahoo.com - February 22 at 9:43 AM
Zynex Sets Fourth Quarter and Full Year 2023 Earnings CallZynex Sets Fourth Quarter and Full Year 2023 Earnings Call
prnewswire.com - February 22 at 9:15 AM
Zynex Introduces New ProductsZynex Introduces New Products
finance.yahoo.com - February 20 at 12:48 PM
Zynex Introduces New ProductsZynex Introduces New Products
prnewswire.com - February 20 at 9:15 AM
Zynex gets FDA clearance for M-Wave muscle stimulation deviceZynex gets FDA clearance for M-Wave muscle stimulation device
msn.com - February 6 at 10:41 AM
Zynex Says FDA Clears M-Wave Neuromuscular Electrical Stimulation DeviceZynex Says FDA Clears M-Wave Neuromuscular Electrical Stimulation Device
markets.businessinsider.com - February 6 at 10:18 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

AxoGen logo

AxoGen

NASDAQ:AXGN
AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.
ViewRay logo

ViewRay

NASDAQ:VRAY
ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. It provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers through a network of direct sales force and distributors. ViewRay, Inc. was founded in 2004 and is headquartered in Denver, Colorado.
Zynex logo

Zynex

NASDAQ:ZYXI
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.